Oral LBH589 in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) and Mantle Cell Lymphoma (MCL)

This study has been terminated.
(Pharmaceutical company request.)
Sponsor:
Collaborator:
Novartis Pharmaceuticals
Information provided by (Responsible Party):
H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier:
NCT01090973
First received: March 18, 2010
Last updated: November 21, 2013
Last verified: January 2012
  Purpose

The purpose of the study is to find out the effects and the safety of an investigational study drug called LBH589 when given to people with relapsed or refractory chronic lymphocytic leukemia (CLL) or mantle cell lymphoma (MCL).


Condition Intervention Phase
Non-Hodgkin's Lymphoma
Drug: LBH589
Phase 2

Study Type: Interventional
Study Design: Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: Phase II Trial of Oral LBH 589, a Novel Histone Deacetylase (HDAC) Inhibitor, in Relapsed or Refractory Chronic Lymphocytic Leukemia and Mantle Cell Lymphoma

Resource links provided by NLM:


Further study details as provided by H. Lee Moffitt Cancer Center and Research Institute:

Primary Outcome Measures:
  • Number of Participants With Desired Response [ Time Frame: 8 weeks (2 cycles) unless treatment continues due to partial or complete response ] [ Designated as safety issue: No ]

    Investigators intended to assess the rate of overall and complete response by World Health Organization (WHO) classification in patients with relapsed or refractory aggressive mantle cell lymphoma (MCL) and chronic lymphocytic leukemia (CLL).

    WHO Performance Scale Measures levels of patient capability: 0 Normal activity; 1 Symptoms, but nearly fully ambulatory; 2 Some bed time, but needs to be in bed <50% of normal daytime; 3 Needs to be in bed >50% of normal daytime; 4 Unable to get out of bed.



Secondary Outcome Measures:
  • Number of Participants With Complete Response (CR) and Partial Response (PR) [ Time Frame: 8 weeks (2 cycles) unless treatment continues due to partial or complete response ] [ Designated as safety issue: No ]

    Investigators intended to determine the complete and partial responses. Chronic Lymphocytic Leukemia (CLL): Using the NCI criteria - - See definitions in the Detailed Description section for a Complete hematologic Remission, and Partial Response.

    Mantle Cell Lymphoma (MCL): Based on the International Workshop to Standardize Response Criteria to NHL (Cheson, JCO 1999) - See definitions in the Detailed Description section for a Complete hematologic Remission, and Partial Response.


  • Response Duration [ Time Frame: 8 weeks (2 cycles) unless treatment continues due to partial or complete response ] [ Designated as safety issue: No ]
    Investigators intended to determine the duration of responses.

  • Progression Free Survival (PFS) Estimate [ Time Frame: 8 weeks (2 cycles) unless treatment continues due to partial or complete response ] [ Designated as safety issue: No ]
    Investigators intended to estimate the progression free survival time

  • Number of Participants With Prolonged Corrected QT (QTc) Interval [ Time Frame: 8 weeks (2 cycles) unless treatment continues due to partial or complete response ] [ Designated as safety issue: No ]
    Investigators intended to monitor the QTc interval in patients receiving oral LBH589

  • Number of Participants With Improved Blood and Lymphatic Evaluation Results [ Time Frame: 8 weeks (2 cycles) unless treatment continues due to partial or complete response ] [ Designated as safety issue: No ]
    Investigators intended to evaluate histone acetylation, cytotoxic mixed lymphocyte reaction (MLR) activity, cytokine profiles, and immunologic synapse alterations through peripheral blood correlative studies

  • Number of Participants With Adverse Events (AEs) [ Time Frame: 8 weeks (2 cycles) unless treatment continues due to partial or complete response ] [ Designated as safety issue: Yes ]

    Investigators intended to evaluate the safety and tolerability profile of LBH589. Assessments would consist of monitoring and recording all adverse events and serious adverse events, the regular monitoring of hematology, blood chemistry and urine values, vital signs, ECOG performance status, and the regular physical examinations and ECG assessments.

    Adverse events will be assessed according to the Common Toxicity Criteria for Adverse Events (CTCAE) version 3.0. CTCAE v3.0 can be accessed on the National Institute of Health (NIH)/NCI website at http://ctep.cancer.gov/forms/CTCAEv3.pdf.



Enrollment: 1
Study Start Date: March 2010
Study Completion Date: March 2011
Primary Completion Date: March 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Oral drug treatment
LBH589 will be given orally (by mouth), 40 mg once-a-day, 3 times weekly every week on days 1, 3 & 5, then 8, 10 &12, then 15, 17 & 19, then 22, 24 & 26.
Drug: LBH589

The LBH589 capsule(s) should be swallowed by mouth with a glass of water (8 ounces noncarbonated) in the morning. The daily dose of LBH589 should be taken at approximately the same time each day. Patients should avoid eating grapefruit, Seville (sour) orange or drinking grapefruit juice or Seville orange juice during the study.

After 2 cycles of treatment, if patients do not demonstrate a partial response or complete response (all of the tumor is gone) to the therapy they will be removed from the study. If patients do obtain a partial (the tumor(s) have decreased in size or number but there are still tumors present) or complete response then treatment will continue until their disease progresses.

Other Names:
  • panobinostat
  • HDAC Inhibitor

Detailed Description:

Response Assessment for Mantle Cell Lymphoma

Based on the International Workshop to Standardize Response Criteria to non-hodgkin's lymphoma (NHL) (Cheson, JCO 1999) a complete hematologic remission will be defined as the following:

  • Disappearance of all evidence of disease.
  • Any positron emission tomography (PET)+ mass prior to therapy must be PET negative after treatment.
  • No palpable spleen or liver
  • If bone marrow involvement prior to therapy, must document clear bone marrow.

Partial response will be defined as:

  • No new areas of disease on clinical exam and regression of previous areas of disease
  • Greater than or equal to 50% decrease in the size of prior disease areas per measurement on computed tomography (CT) scan
  • No new PET+ areas on PET scan
  • No increase in size of liver or spleen

Response Assessment for CLL

Using the National Cancer Institute (NCI) criteria, a complete hematologic remission will be defined as having the following present for 2 or more months:

  • Absence of symptoms attributable to CLL
  • Normal findings on physical examination
  • Absolute lymphocyte count <4000/microL
  • Absolute neutrophil count (ANC) >1500/microL
  • Platelet count >100,000/microL
  • Hemoglobin concentration >11 g/dL (untransfused)
  • Bone marrow lymphocytosis <30 percent
  • No nodules (lymphoid aggregates) on bone marrow biopsy

A partial response per the NCI criteria will be defined as having the following for 2 or more months:

  • A reduction in previously enlarged nodes, spleen, and liver by at · least 50 percent and
  • Absolute neutrophil count ≥1500/microL or
  • Platelet count ≥100,000/microL or
  • Hemoglobin concentration ≥11 g/dL or
  • 50 percent improvement over pretherapy reductions in hemoglobin concentration and/or platelet count
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed
  • Patients must meet the following laboratory criteria (unless dysfunction is due to organ infiltration by lymphoma):

    • ANC ≥ 1.5 x 10^9/L
    • Hemoglobin ≥ 9 g/dl
    • Platelets ≥ 75 x 10^9/L
    • Calculated CrCl ≥50 mL/min (MDRD Formula)
    • Total serum calcium ≥ LLN
    • Total serum magnesium ≥ LLN
    • Aspartic transaminase (AST) and alanine transaminase (ALT) ≤ 2.5 x ULN
    • Serum bilirubin ≤1.5 x ULN
    • Serum potassium ≥ LLN
    • Thyroid stimulating hormone (TSH) ≥ lower limit of normal (LLN) and free T4 within normal limits. Patients are permitted to receive thyroid hormone supplements to treat underlying hypothyroidism.
  • Baseline multiple uptake gate acquisition scan (MUGA) or echocardiogram (ECHO) must demonstrate left ventricular ejection fraction (LVEF) ≥ the lower limit of the institutional normal.
  • Eastern Cooperative Oncology Group (ECOG) Performance Status of ≤ 2
  • Documented MCL by biopsy or CLL by biopsy or flow cytometry.
  • Relapsed or refractory disease despite 1 or more lines of therapy.

Exclusion Criteria:

  • Prior histone deacetylase (HDAC), DAC, HSP90 inhibitors or valproic acid for the treatment of cancer
  • Patients who will need valproic acid for any medical condition during the study or within 5 days prior to first LBH589 treatment
  • Peripheral neuropathy ≥ Common Terminology Criteria for Adverse Events (CTCAE) grade 3
  • Impaired cardiac function or clinically significant cardiac diseases, including any one of the following:

    • Patients with congenital long QT syndrome
    • History or presence of sustained ventricular tachyarrhythmia. (Patients with a history of atrial arrhythmia are eligible but should be discussed with the Sponsor prior to enrollment)
    • History of ventricular fibrillation or torsade de pointes
    • Bradycardia defined as HR< 50 bpm. Patients with pacemakers are eligible if HR ≥ 50 bpm.
    • Screening 12 lead electrocardiogram (ECG) with a QTc > 450 msec
    • Right bundle branch block + left anterior hemiblock (bifascicular block)
    • Myocardial infarction or unstable angina ≤ 6 months prior to starting study drug
    • Other clinically significant heart disease (e.g., congestive heart failure (CHF) New York Heart Association (NYHA) class III or IV , uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)
  • Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of LBH589
  • Patients with diarrhea > CTCAE grade 1
  • Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes or active or uncontrolled infection) including abnormal laboratory values, that could cause unacceptable safety risks or compromise compliance with the protocol
  • Patients using medications that have a relative risk of prolonging the QT interval or inducing torsade de pointes if treatment cannot be discontinued or switched to a different medication prior to starting study drug
  • Have received targeted agents within 2 weeks or within 5 half-lives of the agent and active metabolites (which ever is longer) and who have not recovered from side effects of those therapies.
  • Have received either immunotherapy within < 8 weeks; chemotherapy within < 4 weeks; or radiation therapy to > 30% of marrow-bearing bone within < 2 weeks prior to starting study treatment; or who have not yet recovered from side effects of such therapies.
  • Have undergone major surgery ≤ 4 weeks prior to starting study drug or who have not recovered from side effects of such therapy
  • Women who are pregnant or breast feeding or women of childbearing potential (WOCBP) not using an effective method of birth control. WOCBP are defined as sexually mature women who have not undergone a hysterectomy or who have not been naturally postmenopausal for at least 12 consecutive months (i.e., who has had menses any time in the preceding 12 consecutive months). WOCBP must have a negative serum pregnancy test within 24 hours of receiving the first dose of study medication.
  • Male patients whose sexual partners are WOCBP not using effective birth control
  • Prior malignancy within the last 5 years (except for basal or squamous cell carcinoma, or in situ cancer of the cervix)
  • Known positivity for human immunodeficiency virus (HIV) or hepatitis C; baseline testing for HIV and hepatitis C is not required
  • Significant history of non-compliance to medical regimens or unwilling or unable to comply with the instructions given to him/her by the study staff.
  • Have not received prior therapy for aggressive MCL or CLL.
  • No documentation of disease refractoriness (i.e. progression of disease despite current therapy or recurrence within 3 months of last treatment) or relapse despite prior therapy.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01090973

Locations
United States, Florida
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, United States, 33612
Sponsors and Collaborators
H. Lee Moffitt Cancer Center and Research Institute
Novartis Pharmaceuticals
Investigators
Principal Investigator: Celeste Bello, M.D. H. Lee Moffitt Cancer Center and Research Institute
  More Information

Additional Information:
No publications provided

Responsible Party: H. Lee Moffitt Cancer Center and Research Institute
ClinicalTrials.gov Identifier: NCT01090973     History of Changes
Other Study ID Numbers: MCC-15971, IRB # Pro00000102, CLBH589B25T
Study First Received: March 18, 2010
Results First Received: January 27, 2012
Last Updated: November 21, 2013
Health Authority: United States: Food and Drug Administration
United States: Institutional Review Board

Keywords provided by H. Lee Moffitt Cancer Center and Research Institute:
relapsed
refractory
CLL
chronic lymphocytic leukemia
MCL
mantle cell lymphoma

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Leukemia, Lymphoid
Leukemia, Lymphocytic, Chronic, B-Cell
Lymphoma
Leukemia
Lymphoma, Mantle-Cell
Neoplasms by Histologic Type
Neoplasms
Lymphoproliferative Disorders
Lymphatic Diseases
Immunoproliferative Disorders
Immune System Diseases
Leukemia, B-Cell
Panobinostat
Histone Deacetylase Inhibitors
Antineoplastic Agents
Therapeutic Uses
Pharmacologic Actions
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action

ClinicalTrials.gov processed this record on September 18, 2014